Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...

Article type

Original Article


Article page

193- 198


Authors Details

Parthasarathi Roy*, Srisha Ganguli, Santanu Kumar Tripathi


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 482

PDF Downloaded: 291


Pre-operative minimal-cycloplegia mydriasis for capsulorrhexis in hypermature intumescent cataract


Original Article

Author Details : Parthasarathi Roy*, Srisha Ganguli, Santanu Kumar Tripathi

Volume : 9, Issue : 2, Year : 2023

Article Page : 193-198

https://doi.org/10.18231/j.ijceo.2023.037



Suggest article by email

Get Permission

Abstract

Background:  Conventionally adrenergic-anticholinergic combination eye drops (e.g., phenylephrine-tropicamide) are used for pre-operative pupillary dilatation in cataract surgery. This achieves synergy in dilatation, but anticholinergic-induced cycloplegia makes already tense lens-capsule of intumescent cataract more taut, and completion of capsulorrhexis becomes difficult, often resulting in Argentanian flag sign, peripheral extension. An alternative mydriasis-without-cycloplegia strategy (phenylephrine) is also tried for better maintenance of mydriasis but it’s capsule-slackening effect was not thought of. Making best of both, we practice a ‘minimal-cycloplegia mydriasis’ approach (MCM) comprising of 0.25% tropicamide and 5% phenylephrine, instilled in succession. This study was planned to compare our MCM regimen with the conventional fixed-dose-combination regimen of 0.8% tropicamide and 5% phenylephrine (Standard).

Objectives:  To compare the ease and smoothness of capsulorrhexis and relative incidence of complications, in hypermature intumescent cataract surgery, between ocular instillation of alternative ‘MCM’ regimen and the traditional ‘Standard’ regimen.

Materials and Methods:  The study used a prospective observational 2-arm comparison design. The study commenced with due approval of Institutional Ethics Committee. Sixty-one (61) patients (age range: 42-72yrs, number of Male: Female 19:42) undergoing hypermature intumescent cataract surgery by standard SICS+IOL technique and in whom either of two regimens, MCM or ‘Standard’ were used for papillary dilatation, were observed. Outcome analysis was done by Fisher’s Exact Test.

Results:  Out of a total of 61 cases, 29 received MCM regime and 32 received ‘Standard’ cycloplegic dilator. Difference in dilatation between two groups was statistically non-significant. Frequency of completed rhexis and attainment of post-operative BCVA of 6/12 were higher with MCM regime: p< 0.001 and p< 0.0005 respectively. Anterior chamber reactions on first post-operative day was more frequent with MCM regime (p<0.01), but was transient and cleared totally in a week.

Conclusion:  Minimal-cycloplegia dilatation regime comprising of 0.25% tropicamide and 5% phenylephrine, instilled in succession may be preferred for capsulorrhexis in hypermature intumescent cataract.


How to cite : Roy P, Ganguli S, Tripathi S K, Pre-operative minimal-cycloplegia mydriasis for capsulorrhexis in hypermature intumescent cataract. Indian J Clin Exp Ophthalmol 2023;9(2):193-198

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.